Market Reaction To Bristol-Myers' Mixed Clinical Results: 'A Little Excessive'
August 16, 2017 at 11:59 AM EDT
Credit Suisse termed the market reaction to Bristol-Myers Squibb Co (NYSE: BMY)'s CM-214 data as overly pessimistic. The comment was ...
